1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Lilly Hopes To Differentiate Omvoh In Crohn’s With Histologic Data

 
• By Joseph Haas

The IL-23 antagonist Omvoh is under FDA/EMA review for Crohn’s disease; Lilly reported new Phase III data showing the drug is better than Stelara on multiple endpoints of histologic response.

This is a picture of the Lilly building in San Diego
Lilly is positioning Omvoh against other IL-23 antagonists in Crohn's disease (Shutterstock)

Lilly is awaiting US and EU approvals to add Crohn’s disease to the IL-23 antagonist Omvoh (mirikizumab) and is already thinking about how to differentiate it from competing IL-23 drugs Skyrizi (risankizumab) and Tremfya (guselkumab), which have already shown benefits over Johnson’s established Crohn’s therapy Stelara (ustekinumab) in head-to-head studies.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.

More from Therapy Areas